Profile

Bonnie W. Ramsey, MD

Bonnie W. Ramsey, MD

Pulmonary and Sleep Medicine, Cystic Fibrosis Research

On staff since July 1980

Children's Title: Director, Center for Clinical and Translational Research; Associate Director, Pediatric Clinical Research Center

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

"I became involved in CF research because of my mentor, Arnie Smith, who was devoted to understanding the optimal antibiotic treatments for CF lung disease. Together, we developed TOBI, an inhaled form of the antibiotic tobramycin. Soon after the drug was approved as a commercial product, I happened to be riding a hospital elevator with one of my patients and her mom. The mother turned to me and said, "I want you to know that you and the TOBI you helped develop have changed my childs and our familys lives. We no longer have to live in the hospital. My daughter is now at home and able to be a normal child. Thank you.""

Bonnie W. Ramsey, MD, is director of the Center for Clinical and Translational Research at Seattle Childrens Research Institute. She is the co-PI of the UW Institute for Translational Health Sciences which provides extensive clinical research infrastructure at Seattle Childrens Hospital. She is also the PI for a P30 for Cystic Fibrosis Research from the NIDDK. She is Professor and Vice Chair for research in the Department of Pediatrics and holds the Endowed Chair in Cystic Fibrosis (CF) at the University of Washington School of Medicine.

Dr. Ramsey is member of the American Pediatric Society and the Association of American Physicians. She is an attending physician at Seattle Childrens hospital and Associate director of the CF clinic. Her career has focused on clinical care and research in the field of cystic fibrosis (CF). She is internationally recognized for her work in developing new therapies for patients with CF, and she directs the CF Therapeutics Development Network that directs clinical trials throughout the United States. She is also interested in the ethics of pediatric clinical research and has served on two Institute of Medicine committees focused on this topic. Ramsey has used her expertise in clinical and translational research to help develop infrastructure for research involving pediatric participants at the hospital.

Making A Difference

  • Benefits of CF Drug Confirmed

    A new drug – the first to address the cause of cystic fibrosis – signals a breakthrough for CF patients. ... cont.

  • Possible Secret Revealed

    A discovery about how Pseudomonas interacts with Staphylococcus points the way to understanding its drug resistance and defeating chronic lung infections. ... cont.

  • Harnessing the Power of Research

    A new initiative aims to bring research to more children at the site of care – a bold step to improve outcomes by inspiring more collaboration between clinicians and scientists. ... cont.

Recommendations

  • Jim Camano Island, WA 01.25.11

    Watched the TV Show about Dr. Ramsey & Dr. Smith's work on C.F. I am touched by your science but more by your efforts and want to say how wonderful you both are to commit your life's work to such a worthy cause. Nicely done. Jim S....Camano Island

Overview

Board Certification(s)

Pediatric Pulmonology
Pediatrics

Medical/Professional School

Harvard Medical School, Boston

Residency

Pediatrics, Children's Hospital Boston, Boston

Clinical Interests

Cystic fibrosis

Research Focus Area

Translational Research, Cystic Fibrosis

Awards and Honors

Award Name Award Description Awarded By Award Date
Seattle's Top Doc Seattle Met Magazine 2013
U.S. News Top Doctor U.S. News and World Report 2012
Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
Inventor of the Year University of Washington 2009
"Guide to America's Top Pediatricians" Consumer's Research Council of America 2009

Publications

  • Ashlock MA, Beall RJ, Hamblett NM, Konstan MW, Penland CM, Ramsey BW, Van Dalfsen JM, Wetmore DR, Campbell PW 3rd
    A pipeline of therapies for cystic fibrosis.
    Seminars in respiratory and critical care medicine , 2009 Oct. : 611-26
  • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW
    Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    Contemporary clinical trials , 2009 May : 256-68
  • Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW
    Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
    The Journal of pediatrics , 2009 Feb. : 183-8
  • Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI
    Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan. : 66-70
  • Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW
    Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2007 Aug. 15 : 362-9
  • Ramsey BW
    Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis.
    Proceedings of the American Thoracic Society , 2007 Aug. 1 : 359-63
  • Ramsey BW
    Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?
    Proceedings of the American Thoracic Society , 2007 Aug. 1 : 367-9
  • Mayer-Hamblett N, Ramsey BW, Kronmal RA
    Advancing outcome measures for the new era of drug development in cystic fibrosis.
    Proceedings of the American Thoracic Society , 2007 Aug. 1 : 370-7
  • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
    Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
    Pediatric pulmonology , 2007 July : 610-23
  • Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW
    Association between pulmonary function and sputum biomarkers in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2007 Apr, 15 : 822-8
  • Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW
    Laboratory parameter profiles among patients with cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2007 Apr, : 117-23
  • D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Déziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, Brittnacher M, Hayden HS, Selgrade S, Klausen M, Goodlett DR, Burns JL, Ramsey BW, Miller SI
    Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
    Molecular microbiology , 2007 Apr, : 512-33
  • Hoffman LR, Déziel E, D'Argenio DA, Lépine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI
    Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
    Proceedings of the National Academy of Sciences of the United States of America , 2006 Dec. 26 : 19890-5
  • Sucharew H, Goss CH, Millard SP, Ramsey BW
    Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.
    Contemporary clinical trials , 2006 Dec. : 561-70
  • Ramsey BW
    Appropriate compensation of pediatric research participants: thoughts from an Institute of Medicine committee report.
    The Journal of pediatrics , 2006 July : S15-9
  • Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV
    Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
    Proceedings of the National Academy of Sciences of the United States of America , 2006 May 30 : 8487-92
  • Goss CH, Rubenfeld GD, Ramsey BW, Aitken ML
    Clinical trial participants compared with nonparticipants in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2006 Jan. 1 : 98-104
  • Ernst RK, D'Argenio DA, Ichikawa JK, Bangera MG, Selgrade S, Burns JL, Hiatt P, McCoy K, Brittnacher M, Kas A, Spencer DH, Olson MV, Ramsey BW, Lory S, Miller SI
    Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis.
    Environmental microbiology , 2003 Dec. : 1341-9
  • Rosenfeld M, Ramsey BW, Gibson RL
    Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.
    Current opinion in pulmonary medicine , 2003 Nov. : 492-7
  • Gibson RL, Burns JL, Ramsey BW
    Pathophysiology and management of pulmonary infections in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2003 Oct. 15 : 918-51
  • Ramsey BW
    To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa?
    American journal of respiratory and critical care medicine , 2002 Oct. 1 : 906-7
  • Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW
    Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
    Chest , 2002 July : 219-26

Research Funding

Grant Title Grantor Amount Award Date
Optimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter Randomized Trial Clinical Coordinating Center NIH/NHLBI Sept. 15, 2013
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) Cystic Fibrosis Foundation Therapeutics Oct. 1, 2012
Baby Observational and Nutritional Study of Cystic Fibrosis (BONUS) NIH/NIDDK Aug. 3, 2012
Institute for Translational Health Sciences NIH June 1, 2012
Molecular Biology of Cystic Fibrosis Cystic Fibrosis Foundation Oct. 1, 2011
Early Intervention in CF Exacerbation (eICE Study) Cystic Fibrosis Foundation Therapeutics Aug. 1, 2011
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) NIH/NHLBI Aug. 1, 2011
Infant Nutrition Study of Newborns with Cystic Fibrosis Cystic Fibrosis Foundation Therapeutics Feb. 1, 2011
Newly Acquired MRSA Eradication Protocol Cystic Fibrosis Foundation Therapeutics Sept. 1, 2010
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis NIH/NIDDK July 6, 2010
Early Intervention in Pulmonary Exacerbation in CF NIH/NHLBI July 1, 2010
EPIC Observational Study Cystic Fibrosis Foundation Therapeutics April 1, 2009
Therapeutics Development Network Coordinating Center Cystic Fibrosis Foundation Therapeutics April 1, 2003